Abstract
ObjectiveTo investigate the correlation between CD133-positive gastric cancer and clinicopathological features and its impact on survival.MethodsA search in the Medline and Chinese CNKI (up to 1 Dec 2011) was performed using the following keywords gastric cancer, CD133, AC133, prominin-1 etc. Electronic searches were supplemented by hand searching reference lists, abstracts and proceedings from meetings. Outcomes included overall survival and various clinicopathological features.ResultsA total of 773 gastric cancer patients from 7 studies were included. The median rate of CD133 expression by immunohistochemistry (IHC) was 44.8% (15.2%–57.4%) from 5 studies, and that by reverse transcription polymerase chain reaction (RT-PCR) was 91.3% (66.7%–100%) from 4 studies. The accumulative 5-year overall survival rates of CD133-positive and CD133-negative patients were 21.4% and 55.7%, respectively. Meta-analysis showed that CD133-positive patients had a significant worse 5-year overall survival compared to the negative ones (OR = 0.20, 95% CI 0.14–0.29, P<0.00001). With respect to clinicopathological features, CD133 overexpression by IHC method was closely correlated with tumor size, N stage, lymphatic/vascular infiltration, as well as TNM stage.ConclusionCD133-positive gastric cancer patients had worse prognosis, and was associated with common clinicopathological poor prognostic factors.
Highlights
Gastric cancer (GC) is the fourth most common cancer worldwide [1]
Underwent radical resection and postoperative adjuvant therapy, most of GC patients will die of recurrence and metastasis, with 5-year overall survival no more than 50% for resectable patients in China [2]
Around 67.8% (58.8%–78.9%) of reported patients were identified as metastatic lymph node status
Summary
GC is the second leading cause of cancer-related death in Asia. Underwent radical resection and postoperative adjuvant therapy, most of GC patients will die of recurrence and metastasis, with 5-year overall survival no more than 50% for resectable patients in China [2]. The advancement in survival of GC patients in past few decades was relatively small, due to a lack of deep understanding the molecular mechanism of cancer. CD133 has been used widely as a marker to identify CSC in colon, lung, brain, pancreatic cancer and so on [5,6,7,8]. Its prognostic value for cancer patients has been found in many cancers [9,10,11,12]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
